Download FTO and IRX3 Genes: What Research Shows The official name of

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Epigenetics of depression wikipedia , lookup

Copy-number variation wikipedia , lookup

Genomic imprinting wikipedia , lookup

Oncogenomics wikipedia , lookup

Epigenetics of human development wikipedia , lookup

Point mutation wikipedia , lookup

Genome evolution wikipedia , lookup

Genetic engineering wikipedia , lookup

Epigenetics of neurodegenerative diseases wikipedia , lookup

Gene wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Public health genomics wikipedia , lookup

Neuronal ceroid lipofuscinosis wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

RNA-Seq wikipedia , lookup

Gene desert wikipedia , lookup

Epigenetics in learning and memory wikipedia , lookup

Gene nomenclature wikipedia , lookup

Genome (book) wikipedia , lookup

Gene therapy wikipedia , lookup

Saethre–Chotzen syndrome wikipedia , lookup

History of genetic engineering wikipedia , lookup

Gene expression programming wikipedia , lookup

Therapeutic gene modulation wikipedia , lookup

Epigenetics of diabetes Type 2 wikipedia , lookup

Fetal origins hypothesis wikipedia , lookup

Site-specific recombinase technology wikipedia , lookup

Gene expression profiling wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Microevolution wikipedia , lookup

NEDD9 wikipedia , lookup

Designer baby wikipedia , lookup

Nutriepigenomics wikipedia , lookup

Transcript
FTO and IRX3 Genes: What Research Shows
The official name of this gene is “fat mass and obesity associated.” In 2007, an international
team of researchers proclaimed that they had discovered the first genetic variant linked to
increased obesity risk. People with two copies of the FTO gene were 3 kilograms heavier than
those without the gene.
About 16% of people of European descent have two copies of the gene. Female mice with two
copies of the FTO gene became 22% heavier than normal female mice after 20 weeks on a
standard diet. Male mice with two copies of the FTO gene became 10% heavier than normal
mice. Mice with FTO overactivity ate more food than normal mice, which was believed to
account for the weight gain.
It was found that individuals with variations in obesity genes eat more meals and snacks,
consume more calories per day, and have a greater preference for high-fat and sugary foods.
However, the researchers emphasize that having these genetic traits does not mean that obesity is
inevitable. Making good lifestyle choices still will have a large impact on body weight and
composition.
Individuals with a variant of the FTO and brain-derived neurotrophic factor (BDNF) genes are at
a higher risk for becoming obese. Both genes are expressed in the hypothalamus, where eating
and appetite are controlled. Individuals with BDNF variations consumed more servings from
dairy, meat, eggs, nuts, and beans, and also ate about 100 more calories a day, compared to those
without the variation.
Recent research has found that FTO interacts with the IRX3 gene. It appears that the IRX3 gene
is the functional obesity gene, while the FTO gene itself appears to have only a peripheral effect
on obesity. It was found that disabling the FTO gene in mice does not lead to obesity and that not
all humans with FTO variants are obese. IRX3 seems to control body mass and regulate body
composition.
Mice without the IRX3 gene were significantly leaner than their normal counterparts. They
weighed about 30% less, primarily through reduced fat, despite normal levels of caloric intake
and physical activity. In fact, mice without the IRX3 gene retained the same weight and fat levels
on a high-fat diet that they did on a normal diet. To the contrary, mice with the IRX3 gene
gained almost twice as much fat when fed the high-fat diet. The fat cells in the IRX3-deficient
mice were smaller, the mice had more brown fat, and they were better able to metabolize
glucose.
Elderly people with a common variant of FTO were found to have low blood concentrations of
leptin (the satiety hormone) and high levels of ghrelin (the hunger hormone). In fact, the elderly
individuals with the variant had ghrelin levels about 9% higher and leptin levels about 11%
lower than those without the variant.
FTO indirectly affects the function on the primary cilium, a hairlike appendage on brain and
other cells. The abnormalities of the cilium molecules then increase body weight by affecting the
function of leptin receptors. Researchers from the Columbia University Medical Center found
that when FTO expression was either increased or decreased, a nearby gene RPGRIP1L also
changed expression. RPGRIP1L is known to play a role in regulating the primary cilium, and
mutations in the cilium are implicated in rare forms of obesity. When the FTOs’ intron sequence
was analyzed, it was found to serve as a binding site for the CUX1 protein, which is a
transcription factor that modifies the expression of RPGRIP1L.
When mice were bred in a lab to lack one of their two RPGRIP1L genes, they had a higher food
intake, gained significantly more body weight, and had a higher percentage of body fat, when
compared to controls. In a follow-up experiment, it was found that the RPGRIP1L-deficient mice
also had impaired leptin signaling. Some researchers have speculated that obesity is a ciliopathy,
such as polycystic kidney disease.
University of Alabama at Birmingham researchers speculated that the mutations in the primary
cilia might scramble signaling pathways in the hypothalamus and trigger chronic obesity.
Mutated primary cilia also seem unable to dock the melanin-concentrating hormone (MCH),
which is a key controller of appetite. When the Birmingham researchers looked at genetically
modified mice models of Bardet-Biedl syndrome (a ciliopathy that results in obesity, cystic
kidneys, blindness, mental deficits, and extra toes and fingers), they found that the mice lost
leptin sensitivity when obese, but regained sensitivity when their diet was restricted and they lost
weight. These findings indicate that the leptin sensitivity is a secondary consequence, rather than
a cause, of the obesity.
Previous research from The Ohio State University, found that the MCH receptor, which is
involved in appetite regulation, localizes in primary cilia in normal brain cells known to regulate
eating behavior. In normal brain cells of the hypothalamus, the MCH receptor is in the primary
cilia. However, in the Bardet-Biedl syndrome mice, the MCH receptor was unable to enter the
cilium.
References and recommended readings
American Society for Cell Biology. Is obesity a ciliopathy, triggered by malfunctioning primary
cilia? ScienceDaily® Web site.
http://www.sciencedaily.com/releases/2011/12/111206131442.htm. Published December 15,
2011. Accessed August 7, 2014.
Columbia University Medical Center. Common obesity gene contributes to weight gain.
ScienceDaily Web site. http://www.sciencedaily.com/releases/2014/05/140522175252.htm.
Published May 22, 2014. Accessed August 7, 2014.
Lifespan. ‘Obesity genes’ may influence food choices, eating patterns. ScienceDaily Web site.
http://www.sciencedaily.com/releases/2012/05/120523114847.htm. Published May 23, 2012.
Accessed August 7, 2014.
University of Chicago Medical Center. ‘Master regulator’ of obesity? Distant IRX3 gene appears
to interact with obesity-related FTO gene mutations. ScienceDaily Web site.
http://www.sciencedaily.com/releases/2014/03/140312150057.htm. Published March 12, 2014.
Accessed August 7, 2014.
University of Oxford. Overactive FTO gene does cause overeating and obesity. ScienceDaily
Web site. http://www.sciencedaily.com/releases/2010/11/101116220332.htm. Published
December 6, 2010. Accessed August 7, 2014.
Uppsala Universitet. Obesity gene linked to hormonal changes that favor energy surplus.
ScienceDaily Web site. http://www.sciencedaily.com/releases/2014/06/140611112746.htm.
Published June 11, 2014. Accessed August 7, 2014.
Contributed by Elaine Koontz, RDN, LD/N
Review Date 8/14
G-2060